跳至主要内容
临床试验/NCT04208087
NCT04208087已完成1 期

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of SI-722 Intravesical Instillation in Interstitial Cystitis/Bladder Pain Syndrome Subjects

Seikagaku Corporation5 个研究点 分布在 1 个国家目标入组 33 人开始时间: 2020年3月30日最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
已完成
入组人数
33
试验地点
5
主要终点
Maximum Plasma Concentration (Cmax) for SI-722

研究概览

简要总结

This study is designed randomized, double-blind, placebo-controlled trial in Interstitial Cystitis/Bladder Pain Syndrome patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Sequential
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Males or females, ≥18 and ≤80 years of age
  • A score of 19 or greater on the Bladder Pain/Interstitial Cystitis Symptom Score (BPIC-SS)

排除标准

  • Urinary tract infection ≤30 days
  • Treatment with intravesical therapy ≤60 days
  • Treatment with any opioid therapy ≤7 days
  • History of bladder hydrodistension ≤3 months
  • Has cancer or a past history of any cancer ≤5 years
  • Body mass index (BMI) ≥40 kg/m2

研究组 & 干预措施

SI-722

Experimental

干预措施: SI-722 (Drug)

Placebo

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

Maximum Plasma Concentration (Cmax) for SI-722

时间窗: 4 weeks

SI-722 concentrations in plasma were measured using collected blood samples, and plasma PK parameters for SI-722 were estimated.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验